Treatment of snoring and obstructive sleep apnoea by rapid maxillary expansion

1996 ◽  
Vol 26 (3) ◽  
pp. 428-429 ◽  
Author(s):  
R. G. PALMISANO ◽  
I. WILCOX ◽  
C. E. SULLIVAN ◽  
P. A. CISTULLI
Keyword(s):  
Obstructive Sleep Apnoea ◽  
Sleep Apnoea ◽  
Rapid Maxillary Expansion ◽  
Maxillary Expansion ◽  
Obstructive Sleep

The severity of obstructive sleep apnoea does not influence ambient IGF-I levels

2017 ◽  
Author(s):  
Julie Lynch ◽  
Nikolaos Kyriakakis ◽  
Mark Elliott ◽  
Dipansu Ghosh ◽  
Mitchell Nix ◽  
...  
Keyword(s):  
Obstructive Sleep Apnoea ◽  
Sleep Apnoea ◽  
Obstructive Sleep ◽  
Igf I

Requirement of staged interventions in a complex case of Acromegaly and Obstructive Sleep Apnoea

2020 ◽  
Author(s):  
Mili Dhar ◽  
Jennifer Elias ◽  
Benjamin Field ◽  
Sunil Zachariah ◽  
Julian Emmanuel
Keyword(s):  
Obstructive Sleep Apnoea ◽  
Sleep Apnoea ◽  
Complex Case ◽  
Obstructive Sleep

Obstructive sleep apnoea is highly prevalent in a bariatric surgical population

2020 ◽  
Author(s):  
Rachel Agius ◽  
Claudia Coelho ◽  
James Crane ◽  
Piya Sen Gupta ◽  
Barbara McGowan
Keyword(s):  
Obstructive Sleep Apnoea ◽  
Sleep Apnoea ◽  
Obstructive Sleep

What Non-Alcoholic Fatty Liver Disease Has Got to Do with Obstructive Sleep Apnoea Syndrome and viceversa?

2014 ◽  
Vol 23 (3) ◽  
pp. 291-299 ◽  
Author(s):  
Giovanni Tarantino ◽  
Vincenzo Citro ◽  
Carmine Finelli
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Obstructive Sleep Apnoea ◽  
Fatty Liver Disease ◽  
Sleep Apnoea ◽  
Obstructive Sleep Apnoea Syndrome ◽  
Alcoholic Fatty Liver ◽  
Sleep Apnoea Syndrome ◽  
Obstructive Sleep ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) and obstructive sleep apnoea syndrome (OSAS) are common conditions, frequently encountered in patients with obesity and/or metabolic syndrome. NAFLD and OSAS are complex diseases that involve an interaction of several intertwined factors. Several lines of evidence lend credence to an immune system derangement in these patients, i.e. the low grade chronic inflammation status, reckoned to be the most important factor in causing and maintaining these two illnesses. Furthermore, it is emphasized the main role of spleen involvement, as a novel mechanism. In this review the contribution of the visceral adiposity in both NAFLD and OSAS is stressed as well as the role of intermittent hypoxia. Finally, a post on the prevention of systemic inflammation is made.Abbreviations: ALT: alanine aminotransferase; BMI: body mass index; CCR2: chemokine (C-C motif) receptor 2; CRP: C-reactive protein; CPAP: continuous positive airway pressure; FFA: free fatty acid; IGF-I: insulin-like growth factor; IR: insulin resistance; IL-6: interleukin-6; IH: intermittent hypoxia; IKK-β: IκB kinase β; LPS: lipopolysaccharide; MCP-1: monocyte chemoattractant protein-1; NAFLD: non-alcoholic fatty liver disease; NASH: nonalcoholic steatohepatitis; NEFA: non-esterified fatty acid; NF-κB: nuclear factor-κB; OSAS: obstructive sleep apnoea syndrome; PAI-1: plasminogen activator inhibitor-1; ROS: reactive oxygen species; TNF-α: tumor necrosis factor-α; T2D: type 2 diabetes.

Sign in / Sign up

Export Citation Format

Share Document